

Ref: STEX/OUTCOME/2025-26

Date: 14.11.2025

<b>BSE Limited</b> <b>25th Floor</b> <b>Phiroze Jeejeebhoy Towers Dalal Street,</b> <b>Mumbai 400 001</b>  <b>BSE Code-531146</b>	<b>National Stock Exchange of India Limited</b> <b>Exchange Plaza, C-1,</b> <b>Block - G Bandra Kurla</b> <b>Complex Bandra (East)</b> <b>Mumbai – 400 051</b>  <b>NSE Code: MEDICAMEQ</b>
--	--

**Sub. : Outcome of Board Meeting**

Dear Sir,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025, were approved by the Board of Directors of the Company at its meeting held today at 2.30 P.M. and concluded at 03.45 P.M.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

- The Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2025; as **(Annexure- A)**
- Limited Review Reports from Rai Qimat & Associates, Chartered Accountants on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter as **(Annexure- B)**

We request you to take the same on record.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended on September 30, 2025, as approved by the Board, will also be available on the Company's website [www.medicamen.com](http://www.medicamen.com).

This is for your information and records.

Thanking You.

Yours faithfully,

**For Medicamen Biotech Limited**

PARUL  
CHOUDHARY  
Y  
Parul Choudhary  
Company Secretary  
ACS44157

Digitally signed by  
PARUL CHOUDHARY  
Date: 2025.11.14  
16:12:30 +05'30'



# MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th Sep'2025

## PART I

Particulars	Standalone						Consolidated					
	Three Month period Ended			Half Year Ended			Three Month period Ended			Half Year Ended		
	30.09.2025 Unaudited	30.06.2025 Unaudited	30.09.2024 Unaudited	30.09.2025 Unaudited	30.06.2025 Unaudited	30.09.2024 Unaudited	30.09.2025 Unaudited	30.06.2025 Unaudited	30.09.2024 Unaudited	30.09.2025 Unaudited	30.06.2025 Unaudited	31.03.2025 Audited
<b>1 Income from operations</b>												
(a) Net Sales / Income from operations	4,222.52	3,844.90	4,284.39	8,067.42	8,432.55	15,146.33	4,716.98	4,304.48	4,474.34	9,021.46	8,779.20	16,254.72
(b) Other Income	37.28	47.03	28.96	84.31	86.48	622.51	37.28	47.03	28.96	84.31	87.59	624.39
(c) Total Revenue	4,259.80	3,891.93	4,313.35	8,151.73	8,519.04	15,768.85	4,754.26	4,351.50	4,503.30	9,105.76	8,866.79	16,879.10
<b>2 Expenses</b>												
a) Cost of Material Consumed	2,125.61	2,387.78	2,862.12	4,513.39	5,004.49	8,883.33	2,197.18	2,459.77	2,894.44	4,656.95	5,061.01	9,054.97
b) Purchase of Goods Traded	-	-	-	-	-	-	-	-	-	-	-	-
c) Changes in Inventory of Finished Goods and Work in Progress	118.13	(188.49)	(450.35)	(70.36)	(212.64)	(608.08)	118.13	(188.49)	(450.34)	(70.36)	(207.73)	(603.17)
d) Employees Benefits Expenses	571.22	530.53	512.80	1,101.75	1,060.67	2,157.02	883.08	809.03	763.43	1,692.11	1,546.98	3,187.29
e) Finance Cost	84.12	56.24	101.17	140.36	169.02	304.54	98.89	115.34	104.10	214.23	174.67	315.61
f) Depreciation and Amortisation Expenses	181.04	177.30	257.22	358.34	431.43	696.21	185.67	180.13	260.73	365.80	437.76	706.61
g) Other expenses	902.91	711.65	704.96	1,614.56	1,439.13	3,058.38	1,003.02	762.63	735.30	1,755.65	1,502.83	3,219.80
<b>Total Expenses</b>	3,983.04	3,675.00	3,987.93	7,658.03	7,892.10	14,491.41	4,485.97	4,138.41	4,307.66	8,624.38	8,515.52	15,891.10
<b>Profit/(Loss) before Exceptional Items &amp; Tax (1 - 2)</b>	276.76	216.94	325.42	493.70	626.94	1,277.43	268.29	213.09	195.64	481.38	351.27	988.00
Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	-	-
<b>Profit/(Loss) before Extra Ordinary Items &amp; Tax (3 - 4)</b>	276.76	216.94	325.42	493.70	626.94	1,277.43	268.29	213.09	195.64	481.38	351.27	988.00
<b>Tax Expenses</b>												
Current Year	68.23	56.96	105.25	125.19	188.81	363.95	68.23	56.96	105.25	125.19	188.81	363.95
MAT Credit Entitlement	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Tax Liability	(12.03)	(3.68)	(6.74)	(15.71)	(14.54)	(31.25)	(11.37)	(3.91)	-	-	-	-
<b>Total Tax Expense</b>	56.21	53.27	98.52	109.48	174.27	332.70	56.86	53.05	105.25	109.90	174.27	332.43
<b>Net Profit / Loss for the period from Continuing operation (5 - 6)</b>	220.55	163.66	226.90	384.22	452.67	944.73	211.43	160.05	90.39	371.48	177.00	655.57



*R. Bhandari*

Particulars	Standalone						Consolidated					
	Three Month period Ended			Half Year Ended			Three Month period Ended			Half Year Ended		
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025	30.09.2025	30.06.2025	30.06.2024	30.09.2025	30.09.2024	Year Ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
8 Other Comprehensive Income												
Item that will not be reclassified to Profit & Loss												
9 Total Comprehensive Income net of Tax	220.55	163.66	226.90	384.22	452.67	944.73	211.43	160.05	90.39	371.43	177.00	655.57
10 Net Profit / Loss attributable to												
a) Controlling Interest												
b) Non-controlling Interest												
10 Paid up equity share capital												
(Rs. 10/- per share)												
11 Earning Per Share (Rs.)												
Basic	1.63	1.21	1.78	2.83	3.56	7.43	1.56	1.18	0.71	2.74	1.39	5.16
Diluted	1.63	1.21	1.78	2.83	3.56	7.43	1.56	1.18	0.71	2.74	1.39	5.16

**NOTES :**

- 1 The unaudited financial results for the quarter ended on 30.09.2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14th November, 2025
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- 5 Limited Review Report has been carried out by the Statutory Auditors for the above period.
- 6 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

*R. B. Sharma*

BIOTECH LTD.  
New Delhi

Place : New Delhi  
Dated : 14.11.2025



**MEDICAMEN BIOTECH LIMITED**

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

**STANDALONE CASH FLOW STATEMENT FOR THE PERIOD 01.04.2025 TO 30.09.2025**

Particulars	Standalone		Consolidated	
	For the Half year ended 30th Sept, 2025	For the year ended 31st March, 2025	For the Half year ended 30th Sept, 2025	For the year ended 31st March, 2025
<b><u>CASH FLOW FROM OPERATING ACTIVITIES</u></b>				
Net Profit/(Loss) after tax from continuing operations	384.22	944.75	371.48	655.57
Non-cash adjustment to reconcile profit before tax to net cash flows				
Provision for Taxation	125.19	363.95	125.19	363.95
Adjustment for Deferred Tax	-15.71	-31.25	-15.28	-31.52
Financial Charges	140.36	304.54	214.23	315.61
Loss/(profit) on sale of fixed assets	-	-	-	-
Depreciation/amortization on continuing operation	358.34	696.21	365.80	691.01
Interest income	-65.44	-49.92	-65.44	-50.73
<b>Operating profit before working capital changes</b>	<b>926.95</b>	<b>2,228.29</b>	<b>995.97</b>	<b>1,943.88</b>
Movement of working capital				
Increase/(decrease) in trade payables	-207.66	318.20	53.16	370.29
Increase / (decrease) in long-term provisions	28.96	44.86	28.96	44.86
Increase / (decrease) in short-term provisions	33.35	-450.42	-7.04	-410.18
Increase/(decrease) in other current liabilities	-28.76	-985.52	19.89	-959.11
Decrease/(increase) in trade receivables	-429.52	-1,033.36	-867.09	-1,364.04
Decrease/(increase) in inventories	-663.09	-281.12	-663.10	-276.22
Decrease / (increase) in long-term loans and advances	-270.78	-4.27	-270.78	-2.55
Decrease / (increase) in short-term loans and advances	42.10	138.95	97.20	85.39
Decrease/(increase) in other current assets	-91.28	92.81	-166.47	91.68
Decrease/(increase) in other Non-current assets	-171.89	-196.92	-166.28	-204.88
Direct taxes paid	-295.00	-135.00	-295.00	-135.00
<b>Net cash flow from/ (used in) operating activities (A)</b>	<b>-1,126.62</b>	<b>-263.49</b>	<b>-1,240.58</b>	<b>-815.88</b>
<b><u>CASH FLOWS FROM INVESTING ACTIVITIES</u></b>				
Purchase of fixed assets including intangible & CWIP	-218.19	-191.46	-217.50	-218.85
Purchase of non-current investments	0.00	-30.49	-	50.73
Interest received	65.44	49.92	65.44	28.44
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>-152.75</b>	<b>-172.03</b>	<b>-152.06</b>	<b>-139.68</b>
<b><u>CASH FLOWS FROM FINANCING ACTIVITIES :</u></b>				
Proceeds from issuance of share capital	84.82	-	84.82	-
Proceeds from Securities Premium	4,410.72	-	4,410.72	-
Capital Reserve	-	-	-	52.11
Shares Warrants	861.25	-	861.25	-
Long-term borrowings net of repayment / Repayment	10.92	-18.68	-11.69	247.88
Proceeds from short-term borrowings	345.78	-218.10	554.49	-4.30
Interest paid	-140.36	-304.54	-214.23	-315.61
Dividends paid on equity shares	-	-127.15	-	-127.15
Income Tax Provision reverse for earlier year	-	-	-	-
Preferential issue Expenditure	-300.44	-	-300.44	-
<b>Net cash flow from/(used in) in financing activities (C)</b>	<b>5,272.69</b>	<b>-668.48</b>	<b>5,384.92</b>	<b>-147.06</b>
<b>Net increase/(decrease) in cash and cash equivalents (A + B + C)</b>	<b>3,993.32</b>	<b>-1,104.00</b>	<b>3,992.28</b>	<b>-1,102.62</b>
Cash and cash equivalents at the beginning of the year	358.03	1,462.03	375.94	1,478.56
<b>Cash and cash equivalents at the end of the year</b>	<b>4,351.23</b>	<b>358.03</b>	<b>4,367.93</b>	<b>375.94</b>

For & on behalf of Board of Directors  
Medicamen Biotech Limited



*R. Bishnoi*  
(Rahul Bishnoi)  
Chairman

Place : New Delhi

Dated : 14.11.2025

**MEDICAMEN BIOTECH LIMITED**

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

**STATEMENT OF ASSETS & LIABILITIES**

All Figures in Rs. Lacs				
Particulars	Standalone		Consolidated	
	As at Sep 30,2025 Un-audited	As at Mar 31,2025 Audited	As at Sep 30,2025 Un-audited	As at Mar 31,2025 Audited
<b>A ASSETS</b>				
<b>1 Non-current assets</b>				
(a) Property, Plant and Equipment	8,425.25	8,557.04	8,497.65	8,636.21
(b) Intangible assets	65.87	74.23	65.87	74.23
(c) Capital work-in-progress	-	-	-	-
(d) Financial Assets : Investments	806.14	806.14	806.14	-
(e) Financial Assets : Loans and advances	395.24	124.46	395.24	124.46
(f) Deferred Tax liabilities (Net)	296.17	280.47	296.17	283.00
(g) Other Non- current assets	4,297.19	4,125.30	4,308.50	4,142.21
<b>Total Non-current Assets</b>	<b>14,285.86</b>	<b>13,967.64</b>	<b>14,369.57</b>	<b>13,260.11</b>
<b>2 Current assets</b>				
(a) Inventories	6,876.83	6,213.74	6,876.83	6,213.74
(b) Financial Assets				
(i) Current investments	-	-	-	-
(ii) Trade receivables	6,291.46	5,861.94	7,757.06	6,889.97
(iii) Cash and Bank Balances	4,351.23	358.03	4,367.93	375.94
(iv) Loans and advances	266.75	308.85	266.75	363.95
(c) Other current assets	2,994.77	2,608.48	3,072.81	2,611.34
<b>Total current Assets</b>	<b>20,781.04</b>	<b>15,351.04</b>	<b>22,341.38</b>	<b>16,454.93</b>
<b>Total Assets</b>	<b>35,066.90</b>	<b>29,318.69</b>	<b>36,710.95</b>	<b>29,715.05</b>
<b>B EQUITY AND LIABILITIES</b>				
<b>1 Equity</b>				
(a) Equity share capital	1,356.28	1,271.46	1,356.28	1,271.46
(b) Other Equity	25,848.04	20,492.31	26,184.77	20,033.84
<b>Total Equity</b>	<b>27,204.33</b>	<b>21,763.77</b>	<b>27,541.05</b>	<b>21,305.30</b>
<b>LIBILITIES</b>				
<b>2 Non-current Liabilities</b>				
(a) Financial Liabilities : Borrowings	87.31	76.39	361.74	373.43
(b) Provisions	249.40	220.44	249.40	220.44
(c) Deferred Tax liabilities (Net)	-	-	0.12	-0.30
<b>Total Non-current Liabilities</b>	<b>336.71</b>	<b>296.83</b>	<b>611.27</b>	<b>593.57</b>
<b>3 Current Liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	2,991.25	2,645.47	3,503.12	2,951.87
(ii) Trade payables	3,907.97	4,115.63	4,318.32	4,265.17
(b) Other current liabilities	56.16	84.92	166.70	146.82
(c) Provisions	81.34	79.38	81.34	119.90
(c) Current Tax Liabilities (Net)	489.14	332.69	489.14	332.43
<b>Total Current Liabilities</b>	<b>7,525.86</b>	<b>7,258.09</b>	<b>8,558.63</b>	<b>7,816.18</b>
<b>Total Equity and Liabilities</b>	<b>35,066.90</b>	<b>29,318.69</b>	<b>36,710.95</b>	<b>29,715.05</b>

For & on behalf of Board of Directors  
Medicamen Biotech Limited



*R. Bishnoi*  
(Rahul Bishnoi)  
Chairman

Place : New Delhi

Dated : 14.11.2025



# RAI QIMAT & ASSOCIATES

## CHARTERED ACCOUNTANTS



### LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors,  
Medicamen Biotech Ltd.  
1506, Chiranjiv Tower, 43  
Nehru Place, New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and half year ended on September 30, 2025 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates  
Chartered Accountants

  
Qimat Rai Garg  
Partner

(Membership Number: 080857)  
UDIN: 25080857BMLCWT1382

Place: Gurugram  
Date: 14.11.2025

**LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY CONSOLIDATED  
FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER  
REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE  
REQUIREMENTS) REGULATIONS, 2015**

To

**The Board of Directors,  
Medicamen Biotech Ltd.**  
1506, Chiranjiv Tower, 43  
Nehru Place, New Delhi-110019

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MEDICAMEN BIOTECH LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter and half year ended on September 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.  
  
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited ( the "Subsidiary" Company)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information

required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The Statements includes the Group's share of net profit/(loss) after tax of Rs. (9.12) Lakhs for the quarter ended on September 30, 2025, as considered in the consolidated unaudited financial results, in respect of its subsidiaries, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter.

For Rai Qimat & Associates  
Chartered Accountants



(Membership Number: 080857)  
UDIN: 25080857BMLCWU8410

Place: Gurugram  
Date: 14.11.2025